American Oriental Bioengineering Revenue Growth: -41.08%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AOB Revenue Growth Rankings
| Overall | 3rd percentile | 4288 of 4424 |
| Sector | 7th percentile | 429 of 464 in Healthcare |
| Industry | 15th percentile | 107 of 127 in Biotechnology |
AOB Revenue Growth Range, Past 5 Years
| Minimum | -34.79% | Dec 2002 |
| Maximum | 2349100% | Sep 2001 |
| Average |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these AOB related companies
AOB News
$AOB http://stks.co/21aH Chinese biotech, took a beating today, but with forward p/e of 5.25 will watch.
about 23 days ago by Xiphos_Trading
about 23 days ago by Xiphos_Trading
Halter USX China Index Announces 2011 Year End and 4Q Results and Adds New Constituents
Dec 31, 11:25AM Business Wire
Dec 31, 11:25AM Business Wire
$AOB filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/1BzO
about 86 days ago by MarketBrief
about 86 days ago by MarketBrief
American Oriental Bioengineering Reports Third Quarter 2011 Financial Results
Nov 14, 6:03PM PR Newswire
Nov 14, 6:03PM PR Newswire
URGENT: $AOB filed to delay releasing quarterly earnings results (SEC Filing Form NT 10Q) http://stks.co/13Y8
about 95 days ago by MarketBrief
about 95 days ago by MarketBrief
American Oriental Bioengineering $AOB delays earnings. No reason given (shares were halted as noted earlier)
about 96 days ago by Street_Insider
about 96 days ago by Street_Insider
American Oriental Bioengineering $AOB trading halted with news pending
about 96 days ago by Street_Insider
about 96 days ago by Street_Insider
American Oriental Bioengineering to Announce Third Quarter 2011 Financial Results on November 8, 2011
Nov 03, 9:15AM PR Newswire
Nov 03, 9:15AM PR Newswire
$FSLR $PEIX $NFLX $AOB $CSIQ - I never tire of these cautionary tales, when folks are all gaga http://chart.ly/knacefw
about 124 days ago by meltedcheese
about 124 days ago by meltedcheese
American Oriental Bioengineering (AOB) Submits Plan to Cure Stock Price Deficiency
Oct 06, 5:02PM Street Insider
Oct 06, 5:02PM Street Insider
$AOB http://chart.ly/jph7wuw $AOB yesterday's heavy volume could be the precursor of a strong upside move.
about 184 days ago by ACInvestorBlog
about 184 days ago by ACInvestorBlog
$AOB
American Oriental Bioengineering Reports Q2 EPS $0.05 vs $0.07 Est
about 187 days ago by Benzinga
about 187 days ago by Benzinga
$AOB http://chart.ly/tecrwmk Chinese biotech big vol today stopped at 50-day EMA so on break above - about $1.28
about 220 days ago by StockTiger
about 220 days ago by StockTiger
$AOB http://chart.ly/juap9pf Long term trend is still down.
Heavy resistance in lows $2s
about 308 days ago by WallStreetPro1
about 308 days ago by WallStreetPro1
$AOB http://chart.ly/olnchtg Getting stuck at $2, if it can get over it it may run a little, but $2.20s may be problems too
about 308 days ago by WallStreetPro1
about 308 days ago by WallStreetPro1
$AOB : a huge difference between value and price (assuming it's not fraudulent ). Is this a healthy stock ? I think so !
about 314 days ago by livethelife
about 314 days ago by livethelife
When everyone else is running scared, that's the time to be brave. DD ! $AOB $MSFT $GOOG Buy The Dip ?
about 328 days ago by livethelife
about 328 days ago by livethelife
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AOB | 0.83 | -0.02 | -2.16% | 65.26M |
| EMN | 53.76 | -0.77 | -1.41% | 7.55B |
| BDX | 76.42 | -0.43 | -0.56% | 16.32B |
| FMCN | 23.47 | -0.76 | -3.14% | 3.40B |
| DOW | 34.00 | -0.42 | -1.22% | 40.18B |
| CNTY | 2.72 | 0.07 | 2.64% | 64.95M |
| MRVL | 16.05 | -0.38 | -2.31% | 9.72B |
| LSI | 8.33 | 0.08 | 0.97% | 4.69B |
| DUK | 21.48 | 0.02 | 0.09% | 28.60B |
| PEGA | 29.46 | -0.17 | -0.57% | 1.11B |
